Polygenic Embryo Screening: Where Do We Stand? – ESHRE
European Society of Human Reproduction and Embryology (ESHRE) shared a post on LinkedIn:
“Polygenic Embryo Screening: Where Do We Stand?
Polygenic embryo screening (PES) can now assess IVF embryos for risks of heart disease, diabetes, schizophrenia and cancers. It’s already available, but highly controversial.
The disconnect: patients show strong interest – healthcare professionals have serious concerns.
Join this ESHRE webinar as international experts share new research on these diverging attitudes. Through focused presentations and panel discussion, we’ll explore:
- What drives patient demand vs. professional hesitation
- How views differ across cultures and demographics
- The implications for policy, education and patient care
Be part of shaping how we navigate this emerging frontier in hashtag#ReproductiveGenetics.
Date: 10 February 2026 | 17:00 CET
Find out more.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 22, 2026, 13:13Kate Devine: SREI Advances REI Fellowship Training with Updated Learning Objectives
-
Apr 22, 2026, 13:07Vinesh Gadhia: India Takes the Stage at World AI in Fertility Conference 2026
-
Apr 22, 2026, 11:36Christopher Robinson: Vaginal Clamping of Uterine Arteries in Postpartum Hemorrhage
-
Apr 22, 2026, 11:25Naval Shah: IVF Lab Quality and Standardisation Take Centre Stage at ALPHA 2026
-
Apr 22, 2026, 11:09Khalil Faaed: Recent Updates in AI Are Advancing Embryology and ART
-
Apr 22, 2026, 10:57Donor-Conceived Adults Experience Disclosure in France – RBMO
-
Apr 22, 2026, 10:46Ting Yuan: Metabolic Factors Influencing IVF Success Beyond PCOS
-
Apr 22, 2026, 10:15Strengthening Menopause Care Through Education and Access – SOGC
-
Apr 22, 2026, 10:07Christopher Robinson: Diagnosing High-Tone Pelvic Floor Dysfunction